Masimo Wins $634M Verdict Against Apple in Patent Infringement Case

IRVINE, Calif. – Masimo (MASI), a global leader in medical technology, announced a significant legal victory today. A U.S. District Court jury in California has ruled in favor of Masimo, confirming the validity of their Patent No. 10,433,776 and finding that Apple infringed upon it. The jury awarded Masimo $634 million in damages.

Masimo issued a statement expressing their satisfaction with the outcome: “We are pleased by this outcome, and appreciate the time and attention given to our case by the court and the jury. This is a significant win in our ongoing efforts to protect our innovations and intellectual property, which is crucial to our ability to develop technology that benefits patients. We remain committed to defending our IP rights moving forward.”

This verdict arrives amidst increasing competition in the wearable health technology space. Masimo, primarily known for its advanced monitoring technologies used in hospital settings, has been actively expanding into consumer health products. The patent in question is believed to cover technology related to light-based pulse oximetry, a core component of Masimo’s expertise and a feature now found in many smartwatches, including Apple’s.

The implications of this ruling extend beyond the substantial monetary award. It raises questions about the extent to which tech giants can incorporate existing medical technologies into their consumer devices without proper licensing or independent innovation. Tech analysts suggest that this case could set a precedent, potentially impacting other companies integrating health monitoring features into their products. Several legal experts told CNBC that settlements and licensing agreements may become more common in this sector as a result of this verdict.

From a technological perspective, Masimo’s innovations in signal processing and sensor technology have allowed for more accurate readings in challenging conditions, such as during movement or with low perfusion. This is a critical advantage in clinical settings, and the company has worked to translate this accuracy to consumer-grade wearables.

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET^® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies. Masimo SET^® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements – Masimo
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical facts that address activities, events or developments that we expect, believe or anticipate will or may occur in the future. These forward-looking statements include, among others, statements regarding the outcome of future studies evaluating the real world performance of Masimo SET; and other matters that do not relate strictly to historical facts or statements of assumptions underlying any of the foregoing. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “on-going,” “opportunity,” “plan,” “potential,” “predicts,” “forecast,” “project,” “seek,” “should,” “will,” or “would,” the negative versions of these terms and similar expressions or variations, but the absence of such words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: the ability for clinical studies to recruit eligible participants; the ability for the investigator to collect meaningful data; the design of the clinical protocol; and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC’s website at www.sec.gov. Forward-looking statements are not guarantees of future performance. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.